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The evolution of gene therapy has led to the development of promising new therapeutic approaches. This
NeuroView will introduce the variety of delivery vehicles currently available for gene therapy, a range of
preclinical strategies for tackling major diseases of the nervous system, the clinical limitations, and ethical
considerations.Gene Therapy Grows Up
The concept of gene therapy for human
diseases gained momentum in the 1980s
but was initially met by fear of changing
the human genome and creating new
infectious agents. As fears were lessened
through new regulatory procedures,
inventive spirits in academia and biotech-
nology entered a stage of high enthusiasm
in the 1990s. The explosion in identifica-
tion of disease-associated genes and
generation of genetically authentic animal
models propelled this optimism, and
astounding therapeutic successes in
different animal models suggested that
the timeline for translation into clinical
practice might be years, not decades.
Many human trials later, the reality set in
that this field, like others in medicine,
was confounded by biological differences
between animal models and patients.
By the new millennium, practitioners of
the art had reached a sober conclusion
that translation of gene therapy into the
clinic faced considerable challenges,
namely scaling up delivery from small
animals to humans, unexpected toxicity
and immunogenicity of some vector
systems in humans, and integrative onco-
genesis of vectors. Gene therapists
resolutely continued to improve gene
transfer vectors to enhance the efficiency
and safety of in vivo and ex vivo gene
transfer. Today, the ‘‘new gene therapy’’
includes not only genes, but also oligonu-
cleotides (RNA and DNA) and a variety of
delivery vehicles (nanoparticles, peptides,
liposomes, virus vectors, and cells; Fig-
ure 1). A newwave of clinical trials utilizing
some of these improved gene transfer
vectors is showing very promising results178 Neuron 68, October 21, 2010 ª2010 Else(for a review on clinical applications, see
Gray et al., 2010).
Vehicles and Routes for Genetic
Change
A wide variety of delivery vehicles are
available for gene and/or oligonucleotide
delivery into the nervous system,
including virus vectors, cells, liposomes,
peptides, antibodies, and nanoparticles
(Figure 1). Most preclinical and clinical
studies in the nervous system currently
use AAV vectors, which provide long-
term transgene expression and have an
established safety record, albeit limited
transgene capacity. Oncolytic HSV-1 is
well suited for brain tumor therapy, while
nonreplicating HSV-1 can enter a state
of latency in neurons with continued
transgene expression. Lentivirus vectors,
which can either integrate or remain
episomal in the genome of nondividing
cells, show great promise and have
a larger cargo capacity (Gray et al.,
2010). All these viral vectors have demon-
strated safety and improvements in
disease scores in some clinical trials, but
the small number of patients and open-
label nature of most of these trials
preclude any definitive conclusions on
efficacy. Ongoing efforts to deliver short
nucleic acids are focused on designing
new liposome ‘‘capsules’’ and other types
of nanoparticles and/or artificial delivery
vehicles (Lares et al., 2010).
Although in some diseases focal gene
delivery may be adequate, global delivery
within the nervous system is usually
required (Figure 1B). The distribution of
delivery vehicles within the brain can be
enhanced by convection delivery, wherevier Inc.infusion occurs under constant pressure
over a prolonged period. Migratory cells,
including hematopoietic cells, neuropre-
cursor cells, induced pluripotent stem
(iPS) cells, mesenchymal stromal cells,
and olfactory ensheathing glia can also
be used to deliver gene products to wide
areas in the brain. Some delivery vehicles
and therapeutic proteins can even be
distributed within the brain by axonal
transport (e.g., Passini et al., 2003).
The high vascularization of the brain
offers another route for global distribution.
Though access is limited by the blood-
brain barrier (BBB) in normal adult brain,
access is increased somewhat in dis-
ease states, injury, and tumors, as well
as in the more immature brain. Initial
approaches involved PEGylated immuno-
liposomes formulated with monoclonal
antibodies specific for transferrin and
insulin receptors, to mediate transcytosis
across the BBB. New stealth vectors,
such as chimeric recombinant molecules
carrying a therapeutic protein or RNA
conjugated to antibodies, transcytosis
ligands, or nanoparticles, can also be
effective at crossing the BBB (Lares
et al., 2010). Recently, AAV9 vectors
also joined this highly exclusive BBB-
traversing club. Another route of entry is
the blood-CSF barrier (Figure 1B), which
has been used to achieve widespread
AAV-mediated transgene delivery in
neonatal mice, but with more limited
transduction in adults (Passini et al.,
2003). Unfortunately, vector delivery into
the CSF and blood has a higher risk of
inflammatory immune response as com-
pared to direct delivery into the brain
parenchyma. An interesting alternative is
Figure 1. Combinations of Gene, Vector, Oligonucleotide, and Cell Delivery for Diseases of the Nervous System
(A) Gene composition or expression in cells can be modified by introduction of DNA, RNA oligonucleotides (e.g., siRNA, microRNA), and genes encoded in virus
vectors. These are typically delivered by injection into the brain parenchyma (P) or ventricles (Ve), the spinal cord, or the eye. DNA and/or RNA can also be used to
genetically modify (GM) cells for delivery through injection or vascular infusion. These different vehicles—genes (G), vectors (V), oligonucleotides (O), and cells
(C)—can be combined in different modalities, including ‘‘jump starting’’ primary and stem cells to take on specific phenotypes through transcriptional regulation.
(B) Delivery to extended brain regions can be achieved by injection into the ventricles (Ve) or bymodifying the ventricle lining to produce substances into the CSF.
With direct delivery into the brain parenchyma (P), the range can be expanded by using convection enhanced delivery; by injecting into regions with extensive
neuronal networks (e.g., the thalamus); and by using migratory cells or selectively replicating virus vectors. Access can also be gained through the vasculature
across the blood-brain barrier or the blood-CSF barrier by using hematopoietic cells and vectors; by coupling peptides, antibodies, or other agents to GVOs to
facilitate transcytosis; or by osmotic disruption of tight junctions between cells lining the barrier to temporarily increase permeability. This panel is adapted with
permission from Figure 5 of Abbott et al. (2006), Nature Reviews Neuroscience 7, 41–53.
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lium, choroid plexus, or ependymal cells
to secrete therapeutic proteins into the
brain and CSF.
Changing Genetic Constituency
Replace or Correct Defective Genes
In cases of amutational deficiency (reces-
sive disease), the goal is to replace,
correct, or use substitute genes to regain
normal function. This can be achieved
with the use of viral vectors or DNA
cassettes to express the normal gene in
the brain, or with hematopoietic stem
cells (HSCs) from the patient, which are
genetically modified ex vivo and then rein-troduced. Macrophages derived from the
newly modified HSCs migrate into the
diseased CNS, where they differentiate
into resident microglia expressing the
normal protein. Other promising, though
less efficient, approaches involve direct
gene correction through homologous
recombination, transplicing of correct
gene sequences onto mutant messages
during transcription, and use of antisense
oligonucleotides to suppress some splice
sites or favor new ones in mutant
precursor mRNAs to generate functional
proteins. A dramatic new approach in
vision is to use substitute proteins from
lower organisms, e.g., the opsins, toNeuron 68restore light-sensing defects in eye
diseases, sometimes by turning retinal
ganglionic cells into light-sensing cells
(see Roy et al., 2010).
Suppress Defective Genes
Other hereditary diseases are caused by
mutations producing a defective protein
that itself causes disease (dominant-
negative condition). In this case, one
wants to selectively suppress expression
of the defective transcript while leaving
the normal transcript intact, e.g., through
siRNAs specific to the mutant mRNA.
Downregulation of both mutant and wild-
type alleles may be compatible with ther-
apeutic response, if lowering the normal, October 21, 2010 ª2010 Elsevier Inc. 179
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sion can also be achieved by delivery of
microRNAs, although these often have
off-target effects (Lares et al., 2010).
Target the Downstream Symptoms
Many gene therapy strategies are
directed toward common diseases of
unknown etiology, where the approach
is to target the disease symptoms in
hopes of arresting or reversing the degen-
erative process. Examples include sup-
pressing endogenous Nogo-A, a protein
that inhibits nerve regeneration in multiple
sclerosis (Yang et al., 2010), or suppress-
ing angiogenesis in macular degeneration
by delivery of antisense RNA to VEGF
mRNA or decoy VEGF receptors (Roy
et al., 2010). The delivery of neurotrophic
factors, e.g., nerve growth factor (NGF)
for Alzheimer disease (AD), glial-derived
neurotrophic factor (GDNF), neurturin or
brain-derived neurotrophic factor (BDNF)
for Parkinson disease (PD), and insulin-
like growth factor type 1 (IGF-1) for amyo-
trophic lateral sclerosis (ALS), has also
shown promise. In AD, efforts have also
focused on decreasing extracellular Ab
amyloid load by expressing Ab-specific
single-chain antibodies or the Ab-degrad-
ing protease neprilysin (Ryan et al., 2010;
Lebson et al., 2010) and by regulating Ab
generation (in mice) by accelerating
cholesterol turnover (Hudry et al., 2010).
These approaches have the potential to
arrest or reverse the degenerative pro-
cess, which is not possible with current
medical treatment.
Parkinson disease has been the tar-
get of numerous therapeutic strategies.
Though animal studies indicate that
certain growth factors can restore dopa-
minergic function (e.g., Kells et al.,
2010), this promise has yet to be realized
in clinical trials, raising questions about
the extent to which these animal models
accurately represent the molecular eti-
ology of the disease. Other approaches
involve augmentation of dopamine syn-
thesis by gene delivery of biosynthetic
enzymes (Bjorklund and Kordower, 2010)
or suppression of abnormal subthalamic
activation by focal delivery of the bio-
synthetic enzyme for the inhibitory
neurotransmitter GABA (Feigin et al.,
2007), offering potential prolongation of
L-dopa-like therapeutic effects. It is also
now possible to convert patient fibro-
blasts into replacement dopaminergic180 Neuron 68, October 21, 2010 ª2010 Elseneurons, although they may also
succumb to the degenerative environ-
ment. Finally, RNAi-mediated suppres-
sion of a-synuclein synthesis seems an
obvious approach; however, at least one
study indicates that either up- or downre-
gulation of a-synuclein can produce
degenerative changes in the brain
(Gorbatyuk et al., 2010).
Eliminate Tumor Cells
A huge effort has been devoted to using
gene therapy to extend the life span of
brain tumor patients. Given the urgency
for treatment, with glioblastoma patients
typically dying within a year of diagnosis,
there has been less hesitation to ‘‘pull
out the big guns’’—replicating virus
vectors (Kaur et al., 2009). The range of
viruses explored in this assault is truly
astounding, including a range of human
and animal viruses. The goal is to use
modified viruses that replicate selectively
in tumor cells and spare normal brain
cells. Oncolytic viruses can also be armed
with a variety of genes to kill or suppress
tumor growth (Kaur et al., 2009), including
enzymes that convert prodrugs to chemo-
therapeutic agents within the tumor, cyto-
kines that enhance the immune response
to tumor antigens, and both antiangio-
genic and apoptotic factors. Delivery sys-
tems are being explored to expand the
range of gene delivery, including use of
normal migratory cells that naturally home
to tumor foci in the brain and/or can be
endowed with tumor-targeting ligands.
These cells can be genetically modified
to express therapeutic genes with a
‘‘bystander effect’’ (stealth bombers) or
carry oncolytic viruses within them (Trojan
horses). Although the dire prognosis for
brain tumor patients calls for strong
medicine, the possibility of generating
new human-transmissible virus species
requires strong regulatory oversight.
Promising Near-Therapies
Within the nervous system, several thera-
peutic targets seem close to achieving
benefit in clinical trials, including certain
forms of blindness, lysosomal storage
diseases, and PD. The dramatic success
in restoring some light sensitivity by
vector-mediated delivery of a missing
retinal enzyme to retinal pigment epithe-
lium in patients has been a huge incentive
to gene therapy (Roy et al., 2010).
However, out of all causes of vision lossvier Inc.that might be potentially amenable to
gene therapy, those with unchecked
degeneration or immune inflammatory
reactions will probably not respond to
these therapies long-term. Lysosomal
storage diseases may be amenable to
treatment by either direct injection of virus
vectors or transplantation of a patient’s
hematopoietic stem cells genetically
modified to express the missing protein
(Cartier and Aubourg, 2010). Unfortu-
nately, there is sometimes a need for
very early treatment to prevent unrecover-
able neuronal loss, with limited precedent
for the safety of vectors in children.
Finally, in PD, delivery of genes involved
in synthesis of dopamine in the striatum
or GABA in the subthalamic nucleus offer
promise for relief of motor symptoms.
However, it is not clear how long such
interventions will be effective, as
compared to DBS, given the ongoing
neuronal degeneration. These strategies
also may not ameliorate deficits in other
brain regions associated with depression
and dementia.
Limitations and Ethical
Considerations
Timing and Response
As with other medical treatments, these
approaches should be viewed as ameans
to reduce symptoms and extend viable
life span, rather than as a cure. Presently,
it is impossible to deliver a gene to all
affected cells, and usually some irrevers-
ible damage has occurred prior to diag-
nosis and treatment. The outcome of
gene therapy will probably depend on
factors such as the stage of disease
progression at the time of intervention
and the stability of treatment. For AAV
vectors tested in nonhuman primate
brains, transgene expression remains
stable for at least 8 years. However,
the life span of humans is now in the 80+
years range, and readministration may
be necessary. Critical to establishing the
need for ‘‘refresher’’ therapy will be the
availability of biomarkers to report on
the status of the nervous system, and
vector readministration could be hindered
by potential immunologic neutralization of
the delivery vehicle.
The main risk associated with inte-
grating vectors (e.g., lentivirus vectors) is
the potential for disrupting or activating
gene functions, with the greatest risk
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with stem cells, which are susceptible to
spontaneous mutations that can drive
them down the oncogenic pathway.
Furthermore, in the current state-of-the-
art technology, there is no regulation of
transgene expression and thus no way
to adjust levels of the gene product to
achieve optimal therapeutic intervention,
and if toxic effects ensue there is no way
to stop expression. In some vectors,
a suicide (prodrug-activating) gene is
included so cells producing the transgene
can be killed by prodrug administration in
the case of adverse events.
Risk versus Benefit
Given that gene therapy modalities are
experimental at this stage, the patients
and their families need to be fully informed
about the nature of their illness and the
therapeutic strategy that will be tested in
them. Informed consent is a very serious
and critical process where the patient, or
parents, must weigh the possible risks
and benefits of the procedure. Clearly, if
the illness is life threatening, or neuronal
loss is unremitting, the patient may be
willing to take on a greater degree of risk
of adverse effects. Gene therapy proce-
dures are also often applied when the
disease is well advanced, which may limit
their potential effectiveness. In many
cases the patient and family may agree
to participate solely to help develop
promising therapies for future patients,
who may even be their own familymembers. In less severe diseases, the
less invasive nature of many gene therapy
paradigms may be preferable over
surgical procedures, though gene therapy
may address only a subset of symptoms
or prolong life but with considerable
remaining disabilities.
The appeal of gene therapy is the
promise of more effective treatment for
diseases that have defied other conven-
tional medical modalities. With apparent
clinical successes in blindness, X-linked
adrenoleukodystrophy, and PD, we can
anticipate renewed efforts at the research
level to improve delivery modalities, and
increasing numbers of clinical trials as
everyone becomes more accustomed to
weighing the potential risks and benefits.
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